News
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
17 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
22 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Market-Moving News for March 15th
15 Mar 24
Movers, Trading Ideas
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
1 Mar 24
News, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Reported Earlier, Celldex Therapeutics Prices Upsized $400M Public Offering Of 8.52M Common Stock At $47/Share
1 Mar 24
News
Guggenheim Maintains Buy on Celldex Therapeutics, Raises Price Target to $90
27 Feb 24
News, Price Target, Analyst Ratings
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
26 Feb 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Celldex Therapeutics: Q4 Earnings Insights
26 Feb 24
Earnings
Celldex Therapeutics Earlier Announced Phase 2 Results For Barzolvolimab In Chronic Spontaneous Urticaria Patients, Meeting Primary and Secondary Endpoints
24 Feb 24
News
Celldex Announces Upcoming Presentation Of Barzolvolimab Phase 2 Results In Chronic Spontaneous Urticaria At AAAAI 2024
5 Feb 24
Biotech, News, Events, General
Press releases
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
17 Apr 24
Press Releases
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
8 Mar 24
News, Press Releases
Celldex Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
5 Mar 24
News, Press Releases
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
5 Mar 24
News, IPOs, Press Releases
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
29 Feb 24
Press Releases
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
28 Feb 24
Press Releases
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
26 Feb 24
Earnings, Press Releases
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
24 Feb 24
Press Releases
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
6 Feb 24
News, Health Care, Press Releases
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
5 Feb 24
News, Press Releases